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Dear Editor:
In Asia, an estimated 4.8 million people were living withHIV in 2012.1 Women accounted for a growing proportion
of HIV infections, increasing from 21% in 1990 to 35% in
2009. Gender-based analysis in clinical and operational re-
search is still considered understudied. Better understanding
of the differences in clinical management, care delivery, and
outcomes between males and females in this region may
enhance individualization of treatment and improve efficacy
and safety outcomes of highly active antiretroviral therapy
(HAART). The study objective was to evaluate the effect of
sex on viro-immunological responses to HAART, treatment
outcomes, and toxicities in a regional observational cohort in
the Asia-Pacific.
Established in 2003, the TREAT Asia HIV Observational
Database (TAHOD) is a collaborative observational cohort
study involving 21 sites in 12 countries in the Asia-Pacific
region. Detailed methods have previously been published.2
Briefly, observational data on a range of demographic vari-
ables, clinical outcomes, and laboratory testing results are
semi-annually transferred to a common data management
center. Ethical approvals are obtained from participating
sites, the coordinating center, and the data management and
biostatistics center.
Endpoints for this analysis included changes in CD4 count,
proportions of patients with undetectable HIV viral load at 96
weeks after HAART initiation, rates of new AIDS or death,
loss to follow-up (defined as not seen in clinic for > 12
months), treatment change due to toxicity, and frequency of
CD4 and HIV viral load monitoring. Stepwise multivariate
linear regression and logistic regression models were used to
evaluate the independent associations of baseline variables
with change in CD4 counts and proportion of patients
reaching undetectable HIV viral load ( < 500 copies/mL) at
96 weeks. Multivariate Cox proportional hazards models
were used to determine predictors of new AIDS or death, loss
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to follow-up, and treatment change due to toxicity. P < 0.05
for a two-sided test was considered to be statistically sig-
nificant. Data management and statistical analyses were
performed using SAS for Windows (SAS Institute Inc.,
Cary, NC), and Stata (StataCorp, STATA 10.1 for Windows,
College Station, TX).
A total of 3899 patients were evaluated with a median
follow-up of 3.6 years. At HAART initiation, 71% were male
and the median age was 35 years. The median CD4 cell count
was 113 cells/lL and 47% of patients had a baseline CD4 cell
count below 200 cells/lL. The median CD4 cell count at
HAART initiation was 108 cells/lL for males and 128 cells/
lL for females ( p = 0.094). Significant gender-related dif-
ferences were found in the following baseline parameters:
median age (35 years in males vs. 34 years in females,
p < 0.001), reported injecting drug use (8% vs. 2%,
p < 0.001), CDC category C (45% vs. 34%, p < 0.001), HIV
viral load (median 4.9 log vs. 4.8 log, p = 0.03), positive
HBsAg (12% vs. 6%, p< 0.001), positive anti-HCV (15% vs.
9%, p< 0.001), and presence of anemia (hemoglobin < 13 vs.
< 11g/dL, or 52% vs. 44%, p< 0.001). More females were
taking non-nucleoside reverse transcriptase inhibitor-based
combination ART at baseline (85% vs. 71%, p< 0.001). Fre-
quency of HIV viral load monitoring differed by sex (median
days between tests 180 days formales vs. 238 days for females,
p< 0.001). There was no statistical difference in the frequency
of CD4 monitoring (median days between tests 162 days for
males vs. 169.5 days for females, p= 0.055).
There was no significant difference by gender in CD4
change at 96 weeks (225 vs. 223 cells/lL, p = 0.60). How-
ever, females were more likely to reach undetectable HIV
viral load at 96 weeks after adjustment for other variables (OR
1.7, 95% CI 1.1–2.6, p= 0.024). On the other hand, younger
age (< 25), IDU, and prior use of mono/double ART were less
likely to reach undetectable HIV viral load. Table 1 summa-
rizes the factors associated with undetectable HIV viral load.
Gender was not a predictor of new AIDS events or death
(adjusted HR 0.83, 95% CI 0.62–1.10, p = 0.186) or loss to
follow-up (adjusted HR 1.04, 95% CI 0.8–1.2, p= 0.796).
Females weremore likely to change treatment regimens due to
toxicity (adjusted HR 1.9, 95% CI 1.4–2.7, p< 0.001; Fig. 1).
Common adverse events leading to treatment change in males
were lipodystrophy (30%), skin rash (22%), anemia (13%),
peripheral neuropathy (10%), abnormal liver function (2%),
and diarrhea (2%); and in females were lipodystrophy (43%),
skin rash (24%), anemia (10%), peripheral neuropathy (7%),
and lactic acidosis (3%).
This multi-center observational cohort study showed that
females were more likely to reach undetectable HIV viral
load at 96 weeks after HAART initiation. However, there
were no gender differences in immunological response, and
risk of developing AIDS or death. The frequency of CD4 cell
count monitoring was similar, but females received less HIV
viral load testing. The difference could be explained by the
fact that more females (80%), compared with 57% of males,
were from sites in lower middle/low income countries in
which viral load monitoring is less frequent or absent.
In our study, Asian males had a higher proportion of CDC
category C disease (45% vs. 34%, p < 0.001) and lower me-
dian CD4 cell counts at baseline (108 vs. 128 cells/lL,
p = 0.094) when compared with females, although there was
no significant difference in the risk of developing AIDS or
death. Males in sub-Saharan Africa have been reported to
have higher mortality than females, largely due to late pre-
sentation at more advanced HIV disease.3,4 Studies in Asian
countries also reported difference in health-seeking behavior.
Being male has been associated with late access to ART in
northern Thailand and China’s free ART program.5,6
Consistent with previous studies,7 females were more
likely to switch treatment regimens due to toxicity (adjusted
HR 1.9, 95%CI 1.4–2.7, p< 0.001). Ameta-analysis reported
that females are more prone to develop treatment-related
toxicities.8 Susceptibility to adverse events may differ based
on pharmacokinetics.9 The contributing factors and mecha-
nisms for higher drug exposures in females include differ-
ences in body weight and composition, renal clearance, and
P-glycoprotein activity.10,11
Our study has several limitations. Non-adherence is a
primary cause of virological failure, but ARV drug adherence
Table 1. Factors Associated with Undetectable
HIV Viral Load at 96 Weeks After HAART
Initiation (n= 1359)
Variable OR 95% CI p Value
Gender
Male 1
Female 1.7 (1.1, 2.6) 0.024
Age at HAART initiation (year)
£25 1
26–35 2.0 (1.2, 3.5) 0.011
36–45 2.4 (1.4, 4.3) 0.002
>45 3.1 (1.6, 6.1) 0.001
Mode of infection
Heterosexual contact 1
Homosexual contact 1.3 (0.9, 2.1) 0.165
Injecting drug use 0.2 (0.1, 0.5) < 0.001
Blood products 1.1 (0.2, 5.0) 0.926
Other/ unknown 1.6 (0.7, 3.6) 0.283
Prior treatment (mono or double) before HAART initiation
No 1
Yes 0.4 (0.3, 0.6) < 0.001
CI, confidence interval; HAART, highly active antiretroviral
therapy; OR, odds ratio.
FIG. 1. Time to treatment change due to toxicity by gender.
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data were not included in the analysis. Information on past
ARV exposure for prevention of mother-to-child transmis-
sion is not available in the database, which may have affected
treatment responses. In addition, socioeconomic factors are
important determinants of gender difference in treatment
outcomes but they are not routinely collected.
In conclusion, we observed no significant difference by sex
in the risk of developing new AIDS events or death within our
regional cohort. A higher proportion of females achieved un-
detectable HIV viral load at 96 weeks after HAART initiation.
More males had late disease presentation, while females were
more susceptible to treatment-related adverse events. Con-
tinued research on gender differences in health-seeking be-
havior, treatment access and outcomes is warranted.
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